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The examination of fetal cells, speci®cally erythroblasts, and cell-free fetal DNA from the blood of pregnant women is
currently the subject of intense research with the aim of developing new risk-free methods for prenatal diagnosis. An
unexpected ®nding made during these studies was that the traf®c of fetal erythroblasts into the maternal peripheral
circulation was enhanced in pre-eclampsia. Independent prospective studies examining samples collected in the
second trimester indicated that this perturbation in fetal cell traf®cking occurs early in pregnancy, well before the
onset of pre-eclampsia symptoms. The quantitative analysis of cell-free fetal and maternal DNA levels indicated that
these concentrations were elevated in a co-ordinate manner in manifest pre-eclampsia, and that these elevations
corresponded to disease severity. On the other hand, analysis of prospectively collected samples indicated that only
cell-free fetal but not maternal DNA levels were elevated before onset of symptoms in pregnancies which
subsequently developed pre-eclampsia. These data support hypotheses suggesting that pre-eclampsia is a multi-step
disorder, initiated by a placental lesion that occurs early in pregnancy and which subsequently leads to a systemic
maternal in¯ammatory response and associated endothelial cell damage.
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Fetal cell traf®c in pre-eclampsia
The ®rst cited evidence linking pre-eclampsia with the traf®cking
of fetal cells into the maternal periphery was made during the late
19th century by the German pathologist Schmorl, who detected
multinucleate trophoblast-like cells in the lungs of 14 out of 17
women who had died from eclampsia, but not in four other
pregnant women who had died from other causes (Schmorl,
1893).
Sixty-seven years later, a much more extensive study was
performed when post-mortem material from 220 pregnant women
who had died either during pregnancy, at delivery or shortly post
partum was examined (Attwood and Park, 1960). In this landmark
study it was determined that large trophoblast cells could be
detected in the lungs of almost half the women examined, with the
highest numbers of cells being recorded in cases of eclampsia.
Further studies regarding trophoblast deportation (Douglas et
al., 1959) indicated that this phenomenon was probably common
to all pregnancies. A conundrum of this study was that trophoblast
cells were detected in the uterine vessels but not in the peripheral
circulation. This led to the conclusion that the large trophoblast
cells were rapidly ®ltered from the maternal circulation by the
lungs. A de®cit of the study was that no cases with pre-eclampsia
were included, and so it was impossible to determine whether
trophoblast deportation was increased under such conditions.
More recent studies regarding trophoblast deportation have
included those of Redman's group in Oxford where, as in
previous reports, trophoblast cells could be detected in blood
samples taken from the uterine vein, but not the antecubital vein
(Sargent et al., 1994). In the latter study, trophoblasts were found
in uterine vein samples from 16 of 18 women with pre-eclampsia,
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but only in two of 11 controls. Although this study suggested that
trophoblast deportation was enhanced in pre-eclampsia, no
correlation could be made between the number of cells recovered
and the degree of disease severity.
In 1905, it was suggested that feto-maternal bleeding might be
associated with pre-eclampsia, the proposal being that incompa-
tible fetal bleeding caused eclampsia (Dienst, 1905). Indeed, later
epidemiological studies supported such an idea in that Rh
isoimmunization was observed to be more frequent in pregnancies
affected by pre-eclampsia than in those with normal healthy
deliveries (Knox, 1965, 1968; Pilkington et al., 1966). Although
this suggested that pre-eclampsia was associated with a feto-
maternal haemorrhaging of red cells, the tools needed to address
this issue systematically were only developed much later.
A ®rst step in the direction of being able to quantify the extent
of feto-maternal bleeding was the development of a staining
technique which permitted a distinction to be made between fetal
and maternal erythrocytes (Kleihauer et al., 1957). Using this
technique, it could be shown that the occurrence of fetal
erythrocytes was indeed more frequent in pregnancies affected
by pre-eclampsia than in healthy controls (61 versus 51%) (Jones
et al., 1969). However, this effect was most dramatic in samples
taken before 36 weeks pregnancy, where signi®cant differences in
the numbers of fetal erythrocytes were noted in those pregnancies
subsequently affected by pre-eclampsia, in contrast to those with
normal deliveries.
The detailed analysis of rare nucleated fetal cells from the
maternal circulation was, however, only made possible by the
development of new technologies which permitted the ef®cacious
enrichment of these cells. This was achieved by the use of ¯ow
cytometry (FACS) (Herzenberg et al., 1979) and magnetic cells
sorting (MACS) (Ganshirt-Ahlert et al., 1992; Holzgreve et al.,
1992). Indeed, while exploring the use of the MACS system for
the enrichment of fetal erythroblasts, a fortuitous observation was
made which indicated that the number of erythroblasts was
elevated in the circulation of 43 pregnant women with pre-
eclampsia when compared with 222 controls (Ganshirt et al.,
1994). This ®nding suggested that the traf®cking of fetal
erythroblasts into the maternal circulation might be perturbed in
pre-eclampsia, though as it had not been discerned whether these
erythroblasts were of fetal or maternal origin it was also possible
that this was simply an increase in the number of maternal
erythroblasts. At this time, considerable controversy existed as to
whether any fetal erythroblasts occurred in the maternal
circulation at all (Slunga-Tallberg et al., 1995, 1996).
Consequently, this phenomenon was examined more closely by
means of a case-control study in which only pregnancies with a
singleton male fetus were included (Holzgreve et al., 1998). This
study again strongly suggested that the median number of
erythroblasts was signi®cantly elevated in the maternal periphery
of pregnancies with manifest pre-eclampsia when compared with
a control cohort. Moreover, as only pregnancies with male fetuses
were examined, it was a relatively simple task to determine the
origin of these cells by use of ¯uorescence in-situ hybridization
(FISH) for the X and Y chromosomes. This analysis showed that a
large proportion of the erythroblasts were of fetal origin, and
con®rmed that the traf®cking of fetal cells into the maternal
circulation was elevated in pre-eclampsia.
It is noteworthy that analogous observations regarding
enhanced numbers of fetal erythroblasts in pre-eclampsia have
subsequently been reported independently by other groups,
thereby emphasizing the validity of the original observation (Al
Mufti et al., 2000b; Jansen et al., 2001; Simchen et al., 2001). A
feature observed in all reports made to date was that the numbers
of fetal erythroblasts was not increased in all cases of pre-
eclampsia examined, but that a degree of overlap was seen to exist
between the study group and the controls. However, it is possible
that this might re¯ect the heterogeneous nature of this disorder.
Taken together, these disparate dataÐwhich have been collated
over a period of more than a centuryÐsuggest that pre-eclampsia
is associated with an increased in¯ux of trophoblasts, fetal
erythrocytes and erythroblasts into the maternal circulation. It is
very likely that this traf®c of fetal cells across the placental barrier
is not restricted to these few cell types, but may possibly also
involve fetal immune effector cells and well as a variety of fetal
progenitor cells. It is currently unclear what the effect of the
increased presence of such a diverse variety of semi-allogeneic
cells might be on the mother, and what possible role this event
might play in the manifestation of pre-eclampsia. Nonetheless,
this feature may have important connotations for a recently
proposed hypothesis (Dekker et al., 1998) which suggests that
pre-eclampsia is the result of an immune maladaptation of the
mother to paternal antigens. This aspect is discussed below.
Is fetal cell traf®c enhanced before onset of
pre-eclampsia symptoms?
A consensus among many researchers studying pre-eclampsia is
that the underlying aetiology involves events that occur early
during pregnancy, perhaps even at implantation (Roberts and
Redman, 1993; Dekker and Sibai, 1998). In this way, pre-
eclampsia has been shown to involve alterations in placentation in
that the maternal arteries are not modi®ed from a high pressure
system to one of low pressure with increased blood ¯ow by the
invasive cytotrophoblast (Brosens et al., 1972; Starzyk et al.,
1997). This failure leads to placental hypoxia as the spiral arteries
are unable to provide an adequate blood supply to the placental
villiÐa feature which has severe consequences for the fetus.
Prompted by these speculations, an investigation was made to
determine whether the increase in the number of fetal erythro-
blasts observed in manifest pre-eclampsia was associated with
early defects in placentation, or whether it was a consequence of
later clinically manifest stages of the disorder. For this purpose, a
prospective study was performed in almost 100 pregnant women
from whom maternal blood samples were collected at approxi-
mately 20 weeks gestation (Holzgreve et al., 2001). In order to
increase the cohort size of pregnant women at risk of pre-
eclampsia, 43 cases were selected with a Doppler ultrasound-
identi®ed anomaly of the uterine arteries; this phenomenon has
predictive value in determining those pregnant women who are at
risk of pre-eclampsia or fetal growth retardation (Harrington et
al., 1991). A group of 54 women with no such anomaly was
studied as controls.
Numbers of erythroblasts present in the blood samples were
then determined and compared with the subsequent pregnancy
outcome. On many previous occasions it had been shownÐby
single-cell PCR (Troeger et al., 1999; Di Naro et al., 2000; Zhong
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et al., 2000) or by FISH (Hahn et al., 1999)Ðthat a large
proportion (up to 50%) of the erythroblasts in the maternal
circulation were of fetal origin. Thus, for expediency the total
number of erythroblasts was counted, with no attempt being made
to distinguish between fetal and maternal cells. This strategy also
had the advantage that all of the cases recruited could be
evaluated rather than only those with male fetuses, as current
methods only permit reliable distinction to be made between
single male fetal and maternal erythroblasts on the basis of Y
chromosome-speci®c assays.
The results of the study indicated that fetal cell traf®c, as
measured by total erythroblast numbers, was already elevated at
~20 weeks gestation in those pregnancies which subsequently
developed pre-eclampsia (Holzgreve et al., 2001). A very similar
observation was made independently in an analogous, albeit much
smaller, study in which Doppler ultrasound was used to recruit 18
pregnant women at risk of pre-eclampsia, as well as 10 normal
controls (Al Mufti et al., 2000a).
The predictive value of these studies in detecting pregnant
women at risk for pre-eclampsia, although promising, needs to be
evaluated in further large-scale trials.
Cell-free fetal and maternal DNA levels correspond to
disease severity
The detection of cell-free fetal DNA in the maternal circulation is
a relatively recent ®nding (Lo et al., 1997), while the advent of
real-time PCR technology (Heid et al., 1996), as used by
Taqmanq technology (Applied Biosystems, Inc., Rotkreuz,
Switzerland), has permitted highly reproducible and robust
quantitation of fetal genetic material. By using these techniques,
the median concentration of free fetal DNA was shown to be
elevated ~5-fold in samples obtained from 20 pregnant women
with pre-eclampsia when compared with an equal-sized cohort of
normotensive, pregnant women (Lo et al., 1999).
In performing a more detailed analysis of this phenomenon in a
larger, multi-centre study of 44 women with pre-eclampsia and 53
controls, the striking observation was made that not only were
levels of cell-free fetal DNA elevated in pre-eclampsia, but that a
similar increase in levels of maternal cell-free DNA also occurred
(Zhong et al., 2001b), with both increases being ~10-fold higher
than in controls. Moreover, as the study group was much larger
than was detailed previously (Lo et al., 1999), the pre-eclamptic
cases could be strati®ed according to severity of symptoms. This
analysis, which included three cases with HELLP (haemolysis,
elevated liver enzymes, low platelet count) syndrome and four
with eclampsia, showed that increments in both cell-free fetal and
maternal DNA corresponded to the degree of disease severity. In
addition, a further 3.5-fold increase in cell-free DNA levels was
observed in pregnancies complicated by HELLP syndrome or
eclampsia when compared with those with manifest pre-
eclampsia, or 10-fold greater than in controls. Furthermore, it
could also be shown that levels of the two cell-free DNA species
corresponded to each other in pregnancies affected by pre-
eclampsia, but not in normal pregnancies.
Recently, a very similar observation was reported regarding
cell-free fetal DNA and maternal DNA levels in pregnancies with
pre-eclampsia and those further complicated with HELLP
syndrome (Swinkels et al., 2002). Of particular interest was that
these authors also observed almost 4-fold additional increments in
both cell-free fetal and maternal DNA levels among pregnancies
additionally complicated by HELLP syndrome compared to those
with manifest pre-eclampsia. Levels of cell-free maternal DNA
were also similarly elevated. Taken together, these independent
data sets strongly suggest that increased disease severity is
associated with increased release of cell-free fetal and maternal
DNA into the maternal circulation.
Another group, in a recent study, also examined cell-free fetal
DNA levels in pregnancies affected by pre-eclampsia (Smid et al.,
2001). Although the study cohort was very small, these authors
also observed almost 4-fold elevations in median levels of cell-
free DNA in 10 women with pre-eclampsia.
As with studies reporting fetal cell numbers, investigations into
cell-free fetal DNA indicated a fair degree of overlap between
levels of cell-free DNA in normal pregnancies and those with
manifest pre-eclampsia. In the two studies described (Zhong et al.,
2001b; Swinkels et al., 2002), the latter of which included several
cases with HELLP syndrome, the distinction was much more
apparent between controls and those women with pregnancies
affected by pre-eclampsia. Hence, it has been suggested that an
analysis of cell-free fetal and maternal DNA levels might be of
assistance in the clinical diagnosis of pregnancies affected by
HELLP syndrome (Swinkels et al., 2002).
Cell-free, but not maternal DNA, is elevated before onset
of pre-eclampsia
Currently, two groups (Al Mufti et al., 2000a; Holzgreve et al.,
2001) have shown that the traf®c of fetal cells into the maternal
periphery is enhanced before the onset of pre-eclampsia symptoms.
Consequently, a natural extension of these ®ndings was to examine
whether cell-free fetal DNA levels were similarly elevated.
By examining samples collected previously and prospectively
for the analysis of erythroblast numbers, median cell-free fetal
DNA levels were indeed seen to be elevated ~3-fold in the 10
women who subsequently developed pre-eclampsia, compared
with the 40 controls who delivered normally (Zhong et al., 2001a,
2002a). Likewise, an almost 2-fold increase in median cell-free
DNA level was noted in a study that compared 18 pregnant
women who subsequently developed pre-eclampsia with a group
of 33 women who delivered normally (Leung et al., 2001a).
One very recent report veri®ed these ®ndings in a large group
of early second-trimester (~15 weeks) samples (Cotter et al.,
2002). In this study, samples obtained from 88 women who
subsequently developed pre-eclampsia, were compared with 176
control samples. The analysis indicated that an increase in the
concentration of cell-free fetal DNA was associated with an
almost 8-fold increased risk of developing pre-eclampsia.
It is important to note that in neither of the above studies was
any increase in cell-free maternal DNA observed during the early
stages of pregnancies which subsequently developed pre-eclamp-
sia.
Fetal cell traf®c, cell-free DNA and current hypotheses of
pre-eclampsia
As discussed earlier, data obtained from a variety of sources have
shown that pre-eclampsia is associated with increased traf®cking
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of fetal cells across the placental barrier into the maternal
circulation (Ganshirt et al., 1994; Holzgreve et al., 1998; Al Mufti
et al., 2000b; Jansen et al., 2001). Studies performed on samples
collected prospectively during the second trimester further
indicate that this perturbation occurs early in those pregnancies
which will subsequently develop pre-eclampsia (Al Mufti et al.,
2000a; Holzgreve et al., 2001). These data therefore suggest that
the underlying placental lesions leading to the increased traf®c of
fetal cells into the maternal periphery occur early in those
pregnancies which subsequently develop pre-eclampsia. This
correlates well with previous reports which indicate that placental
defects associated with pre-eclampsia most likely occur early
during gestation (Brosens et al., 1972; Starzyk et al., 1997).
In a similar manner, it has been shown that cell-free fetal DNA
levels are also elevated long before onset of clinical symptoms of
pre-eclampsia (Leung et al., 2001a; Zhong et al., 2001a, 2002b).
The data relating to cell-free DNA, however, have provided an
additional unexpected insight regarding the aetiology of pre-
eclampsia. Recent evidence indicates that cell-free fetal DNA is
most likely of placental origin (Bianchi and Lo, 2001) and is not
derived from fetal cells which have traversed the placental barrier
(Zhong et al., 2002b). It is, furthermore, proposed that cell-free
DNA is liberated by some form of cell turnover or cell death
(Holdenrieder et al., 1999; Stroun et al., 2001). Therefore, the
increased presence of cell-free fetal DNA indicates that pre-
eclampsia is associated with damage to the placenta (Zhong et al.,
2001b). That cell-free fetal DNA levels are elevated before
disease onset also indicates that the placental lesion occurs well
before the clinical symptoms are established. On the other hand,
the increments in cell-free maternal DNA observed once the
disorder has become manifest indicate that this stage, but not the a
symptomatic preclinical stage, is associated with some form of
cell damage in the mother.
In addition, it has been observed (Zhong et al., 2001b; Swinkels
et al., 2002) that the degree of free DNA liberation correlates with
disease severity, which implies that the more severe forms of this
disorder are associated with increased levels of damage to the
placental and maternal tissues
In the present authors' view, these two aspects of fetal and
maternal circulatory DNA levels in pre-eclampsia can best be
reconciled to a model whereby localized placental damage leads
to a more systemic damage of maternal tissues. In this manner, the
present data might add new insight supporting two standing
hypotheses, namely that pre-eclampsia involves the systemic
damage of the maternal endothelium (Roberts et al., 1991a,b) and
that the causative agent for such damage might be the release of
placental toxins, in the form of microscopic cell debris (Redman
and Sargent, 2000). In this regard, a number of experiments have
indicated that such placental microdebris can cause the activation
and destruction of endothelial cells in vitro (Smarason et al.,
1993; Cockell et al., 1997; Knight et al., 1998). It has been
proposed furthermore that this placental subcellular debris could
lead to the unspeci®c activation of the maternal immune system,
leading to a maternal in¯ammatory response in normal pregnancy
(Redman and Sargent, 2000, 2001). The elevated release of these
particles in pre-eclampsia would then lead to a hyperactivation of
the maternal immune system in pre-eclampsia (Johansen et al.,
1999; Redman et al., 1999). The in¯ammatory cytokines, which
would include factors such as tumour necrosis factor (TNF)-a and
interferon (IFN)-g, released by these immune effector cells could
themselves have negative effects both on the placental trophoblast
(Yui et al., 1994) as well as on the maternal endothelium (Choy et
al., 2001). This would potentiate the cascade of in¯ammatory
events, leading to pre-eclampsia (Redman et al., 1999).
It is therefore proposed that the release of free fetal DNA might
be the result of placental breakdown or damage, and that this
process is associated with the release of subcellular particles
(Figure 1A). This proposal is supported by data indicating that the
release of placental microdebris is an intrinsic feature of the
differentiation of the rapidly dividing cytotrophoblast cells into
the resting multinucleate syncytiotrophoblast cell layer, and that
this feature is disturbed under conditions of pre-eclampsia
(Huppertz et al., 1999, 2001). As this process involves
apoptosis-like processes (Huppertz et al., 1999), it is highly
likely that the excess redundant nuclei of the syncytiotrophoblast
are released as cell-free DNA into the maternal circulation.
Further support for this hypothesis is provided by reports
indicating that increased levels of apoptosis, both in placental
bed cytotrophoblasts and in the syncytiotrophoblast layer, occur
in pre-eclampsia (Di Federico et al., 1999; Leung et al., 2001b). It
is, therefore, possible, that such increased levels of cell death may
lead to corresponding increased liberation of cell-free fetal DNA.
Since it has been shown that the interaction of placental
microparticles with the endothelium leads to the destruction of
endothelial cells (Knight et al., 1998), it is feasible that this step
would responsible for the elevated release of free maternal DNA
(Figure 1B). In this manner, the measurement of cell-free fetal
DNA would be indicative of the amount of in¯ammatory
subcellular debris released by the placenta, whereas the measure-
ment of maternal cell-free DNA would be indicative of the extent
of maternal endothelial cell damage (Figure 1A and B). Of
interest is the fact that our data predict two distinct stages in this
cascade: (i) an initiating asymptomatic phase involving a
placental lesion responsible for the release of placental micro-
particles; and (ii) a secondary symptomatic phase involving the
destruction of the maternal endothelium. Therefore, our model
supports proposals made previously regarding the aetiology and
initiation of pre-eclampsia (Redman and Sargent, 2001).
Further experiments will be necessary to test this new
hypothesis, and should include in-vitro systems to test the release
of the microparticles and cell-free DNA by placental explants
under different conditions, as well as an examination of these two
parameters in clinical samples.
Could enhanced fetal cell traf®c aggravate the `immune
maladaptation' of pre-eclampsia?
A recent reinterpretation of epidemiological data has indicated that
pre-eclampsia might be associated with primipaternity rather than
primiparity, in that a change of partner leads to a similar increased
risk of pre-eclampsia as for ®rstborn (Robillard et al., 1999). In
pursuing these observations, a hypothesis was developed that pre-
eclampsia might result from an incorrect immune response by the
mother to paternal antigens (Dekker et al., 1998). Support for this
hypothesis of `immune maladaptation' was obtained from several
epidemiological studies. The data indicated, among other things,
that prolonged exposure to the partner's semen can have a
protective effect and reduce the risk of pre-eclampsia, whereas the
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use of condoms, by which the mother is shielded from exposure to
paternal antigens, can increase the risk (Dekker, 1999; Tubbergen
et al., 1999; Koelman et al., 2000). Elegant proof for this concept
was obtained recently when pregnancies resulting from IVF
involving ICSI were examined (Wang et al., 2002). Here, the rate
of pre-eclampsia was found to be signi®cantly higher in those
pregnancies where the partner was aspermic (and where as a
consequence the mother was never exposed to the partner's semen)
than in other comparable IVF pregnancies where the mother was
exposed to paternal semen. Additional pertinent evidence indicat-
ing that pre-eclampsia might result from an incorrect immune
response to the semi-allogeneic fetus (foreign paternal antigens) is
provided by data obtained from pregnancies resulting from oocyte
donation, where the entire fetus is foreign (both the male and
female complements). In these instances almost 50% of these
pregnancies developed pre-eclampsia (Salha et al., 1999). It
appears therefore that pre-eclampsia is associated with a break-
down in the exquisitely controlled tolerance that exists between
mother and fetus during pregnancy.
The question arises, therefore, as to what might be the effect on
a potentially imbalanced maternal immune response to foreign
fetal antigens, under conditions which lead to a signi®cantly
higher in¯ux of semi-allogeneic fetal cells into the maternal
circulation. It is to be expected that the presence of such foreign
cells will be deleterious. It has been shown that the transplacental
traf®cking of fetal cells is elevated early during gestation, before
the onset of pre-eclamptic symptoms; consequently, it is possible
that this in¯ux of foreign cells might provide a vital trigger in the
development of the disorder. In this manner, the increase in
foreign fetal material might contribute to the overt in¯ammatory
response of the maternal immune system, which has been
postulated to occur in pre-eclampsia (Redman et al., 1999).
It is unclear whether the presence of increased amounts of fetal
DNA could also contribute to the development of this pathology.
Although foreign DNA has been shown to be capable of
integrating into host cells and thereby permitting the expression
of foreign genes (Garcia-Olmo et al., 1999, 2000), it should be
borne in mind that the quantity of fetal DNA present in the
Figure 1. Model reconciling the release of placental microdebris and endothelial disruption with the elevated
release of cell-free fetal and maternal DNA in pre-eclampsia. (A) The release of placental microdebris by the
placental villi would be accompanied by the concomitant release of cell-free fetal DNA. (B) In pre-eclampsia,
the increased release of these placental subcellular particles, accompanied by an increased release of cell-free
fetal DNA, would lead to dysfunction of the maternal endothelium, leading to the release of cell-free maternal
DNA. This system would be exasperated by the parallel overt activation of the maternal immune system, which
would have negative effects both on the placental trophoblast and on the maternal endothelium (B).
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maternal circulation represents only a very small fraction (1±5%)
of the total cell-free DNA (Lo et al., 1998). It is therefore possible
that this large reservoir of cell-free maternal DNA acts as a sink,
effectively diluting out the potential deleterious effects of foreign
fetal DNA. It is clear that further studies will be necessary to
clarify these pertinent issues.
Is enhanced fetal cell traf®c associated with disorders
during pregnancy or post partum?
Recent studies have indicated that fetal cells which have entered
the maternal circulation could potentially be involved in a variety
of maternal disorders (Bianchi, 2000). These include the
pregnancy-associated disorders, polymorphic eruptions of preg-
nancy (PEP) (Aractingi et al., 1998) or thyroiditis (Srivatsa et al.,
2001). It has also been suggested that persisting fetal lymphoid
progenitor cells could play a role in the development of certain
autoimmune disorders such as systemic sclerosis (Nelson et al.,
1998) or systemic lupus erythematosus (SLE) (Johnson et al.,
2001). It is also possible that possible that maternal cells which
have entered the fetal circulation may play a role in certain
juvenile or adult disorders (Artlett et al., 2000, 2001).
As several studies have shown that elevated numbers of fetal
cells enter the maternal circulation in pre-eclampsia, it is enticing
to speculate that this may increase the predisposition of such
women or their children to these disorders with autoimmune
character. In this regard, it is worth noting that the incidence of
both pre-eclampsia (Knuist et al., 1998) and scleroderma (Burns
et al., 1996; Laing et al., 1997) is increased in certain ethnic
population groups, such as Afro-Americans when compared with
Caucasians. In addition, the onset of scleroderma occurs earlier
and in a more severe form among the Afro-American population.
Thus, might a link exist between these two disorders?
By contrast, the ®nding that enhanced traf®cking of maternal
cells into the fetal periphery may occur in pre-eclampsia, and that
this may have deleterious effects on the child, has been indirectly
suggested by two high-pro®le case reports. In the ®rst, an instance
of early-onset sarcoidosis (an autoimmune disorder) was reported
in a 4-year-old child (Falcini et al., 1999), whilst in the second case
the transplacental transmission from mother to child of a natural
killer lymphoma was reported (Catlin et al., 1999). Of interest was
that both pregnancies were affected by pre-eclampsia, and it is
therefore open to speculation whether an increased release of
maternal cells occurred into the fetal circulation in these situations.
These questions are very dif®cult to address due to the
relatively low incidence of pre-eclampsia, and especially of
autoimmune disorders such as scleroderma, and will require the
analysis of large data sets, perhaps of speci®c ethnic groups.
Nevertheless, it is felt that such studies may yield an unexpected
insight into the aetiology of certain autoimmune disorders, in the
same manner that complications of the fetus during pregnancy or
childbirth have been suggested to be involved in the development
of numerous disorders in adult life, for example hypertension
(Barker, 2001).
Conclusions
The association of fetal cell traf®c and pre-eclampsia has been
both long and tenuous, and only recent developments in
technology that permit the reliable isolation and characterization
of rare fetal cells from the maternal periphery have allowed the
substantiation and extension of descriptive reports and specula-
tions ®rst made during the 19th century. In this regard, much of
the data which have recently been obtained are an expected
consequence of research performed on the possible use of fetal
cells and cell-free fetal DNA for non-invasive prenatal diagnosis.
During the time since our original chance ®nding, several
independent studies have shown that pre-eclampsia is associated
with an underlying placental lesion which facilitates the increased
traf®cking of fetal cells, and the release of cell-free fetal DNA.
These studies have also shown that this placental defect occurs
early in pregnancy, long before the onset of any clinical
symptoms. Interestingly, this preclinical phase is only associated
with an increased release of cell-free fetal DNA, whereas the later
clinically manifest stage is also associated with an increased
release of cell-free maternal DNA. It is proposed that these data
could be used to support a model whereby pre-eclampsia results
from the release of placental microparticles which cause wide-
spread disruption of the maternal endothelium. In this regard, the
present data indicate that this process involves two distinct stages:
an initiating placental lesion, associated with the release of cell-
free fetal DNA and toxic debris; this subsequently leads to the
clinical maternal syndrome in a second stage involving the
maternal endothelium, which is associated with the increased
release of free maternal DNA.
One feature which will need to be addressed more carefully in
future is the impact of increased numbers of fetal cells expressing
foreign (paternal) antigens on a maladapted maternal immune
system, and whether this leads to the development of an overt
in¯ammatory response. Indeed, such an imbalance of the maternal
immune response has been postulated to be a key event in the
development of pre-eclampsia. It will also be necessary to
determine the role that cell-free fetal DNA plays in the
manifestation of this disorder. It is therefore, essential to
appreciate how rapidly these new insights into this enigmatic
disorder have been obtained from apparently unrelated events,
namely the traf®cking of fetal cells and the release of cell-free
DNA.
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